Abstract: The present invention relates to a neovascularization inhibitor comprising as the active ingredient N-(3,4-dimethoxycinnamoyl) anthranilic acid represented by the formula: or a pharmaceutically acceptable salt thereof, which has inhibitory effects on proliferation and chemotaxis of human microvascular endothelial cells and tube formation of human microvascular endothelial cells, and therefore, is useful as an agent for the prevention and treatment of diseases associated with neovascularization such as diabetic retino senile discoid macular degeneration, neovascular glaucoma and rheumatic arthritis.

Abstract: The present invention relates to a secondary cataract inhibitor comprising as the active ingredient N-(3,4-dimethoxy-cinnamoyl)anthranilic acid represented by the formula: or a pharmaceutically acceptable salt thereof, which has an inhibitory activity on posterior capsule opacification formation after cataract surgery and is useful for the prevention or treatment of secondary cataract.

Abstract: The present invention relates to indole derivatives represented by the general formula: (wherein R represents an ethyl group or a 2,2,2-trifluoroethyl group; Y represents a hydroxy group or a pivaloyloxy group; and the carbon atom marked with (R) represents a carbon atom in (R) configuration) and pharmaceutically acceptable salts thereof, which have potent and prolonged reducing effects on intraocular pressure and are useful as agents for lowering intraocular pressure.

Abstract: The present invention relates to an agent inhibiting progress of pterygium and postoperative recurrence of the same. N-(3,4-Dimethoxycinnamoyl)anthranilic acid represented by the formula: ##STR1## or a pharmaceutically acceptable salt thereof has an inhibitory activity on proliferation of pterygium tissues, and a pharmaceutical composition comprising as the active ingredient the same is useful as an agent inhibiting progress of pterygium and postoperative recurrence of the same.

Abstract: In preferred embodiments this invention provides a pharmaceutical composition and a method for the treatment of allergic conjunctivitis or allergic rhinitis. The composition is an aqueous solution containing N-(3,4-dimethoxycinnamoyl)anthranilic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition additionally contains as essential components polyvinylpyrrolidone, a basic compound and a surface active agent in prescribed quantities, and the composition has a pH of about 6.5-8.5.

Abstract: In one embodiment this invention provides novel 2-pyrrolidone-5-carboxylic acid compounds, and pharmaceutically acceptable salts thereof, represented by the formula: ##STR1## where n is an integer with a value of 1-4. The compounds have application in the treatment of mental disorders such as dementia and amnesis.

Abstract: In one embodiment this invention provides novel thiazolidine compounds, such as 3-[R-(-)-3-benzyloxycarbonylthiazolidine-4-carbonyl]thiazolidine corresponding to the formula: ##STR1## An invention thiazolidine compound exhibits prolyl endopeplidase inhibitory activity, and has utility as a therapeutic agent for the treatment of dementia and amnesia disorders.

Abstract: The imidazole derivatives of the formula: ##STR1## wherein R is a hydrogen atom or an alkyl group, A.sub.1 and A.sub.2, which may be the same or different, each is an alkylene or an alkylene group, m is 0 or 1, and Z is ##STR2## wherein R.sub.1 and R.sub.2, which may be the same or different, each is a hydrogen atom or an alkyl group, and the terminal carbon atom bonded to the hetero atom of Z may be bonded to either A.sub.1 or A.sub.2 or COOR group (in the case of m being 0); and the pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from human or bovine platelet microsomes, and are useful as therapeutically actives for inflammation, hypertension, thrombus, cerebral apoplexy and asthma.

Abstract: The imidazole compounds of the general formula (I): ##STR1## wherein Y is a carboxyl group, a hydroxymethyl group, an N-di or -mono alkyl substituted or unsubstituted carbamoyl group, a cyano group, or an N-di or -mono alkyl substituted or unsubstituted aminomethyl group, and n is an integer of 3 to 20; and pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from rabbit platelet microsomes, and are useful as therapeutically active agents for inflammation, hypertension, thrombus, cerebral apoplexy and asthma.

Abstract: Novel imidazole derivatives of the general formula (I): ##STR1## wherein Y is a carboxyl group, an alkoxycarbonyl group, a cyano group, a hydroxymethyl group, an aminomethyl group, a formyl group or a carbamoyl group, and A and B, which may be the same or different, each is a straight- or branched-chain alkylene or alkenylene group, and n and m, which may be the same or different, each is zero or 1, with the proviso that when A is methylene group or n is zero, m is 1; and pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from rabbit platelet microsomes, and are useful as therapeutically active agents for the treatment of inflammation, hypertension, thrombus, cerebral apoplexy and asthma.

Abstract: Aromatic carboxylic amides of the general formula: ##STR1## wherein each of R.sub.1 and R.sub.2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R.sub.3 and R.sub.4 are hydrogen atoms or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxyl group containing 1-4 carbon atoms, and may be the same or different, and n is an integer of 1-3, provided that when two Xs are alkyl or alkoxyl groups, the alkyl groups thereof may be connected together into an alkylene group, and the pharmaceutically acceptable salts thereof, possess a strong antiallergic action and are thus useful for treatment of asthma, hay fever, urticaria and atopic dermatitis.

Abstract: New aromatic amidocarboxylic acid derivatives of the general formula: ##STR1## wherein R.sub.1 and R.sub.2 each represent a hydrogen atom or an alkyl gp with 1-4 carbon atoms; R.sub.3 and R.sub.

Abstract: Novel aromatic carboxylic amides of the general formula: ##EQU1## wherein each of R.sub.1 and R.sub.2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R.sub.3 and R.sub.4 are hydrogen atoms or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group containing 1-4 carbon atoms, and n is an integer of 1-3, with the proviso that when two Xs are alkyl or alkoxy groups, they may be connected together to form a ring, as well as pharmaceutically acceptable salts thereof.These compounds possess a strong antiallergenic action and are thus useful for treatment of asthma, hay fever, anticaria and atopic dermatitis.The above aromatic carboxylic amides can be prepared by reacting a reactive functional derivative of the general formula: ##EQU2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.

Abstract: Novel aromatic carboxylic amides of the general formula: ##STR1## wherein each of R.sub.1 and R.sub.2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R.sub.3 and R.sub.4 are hydrogen atoms or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group containing 1-4 carbon atoms, and n is an integer of 1-3 with the proviso that when .[.Xs.]. .Iadd.X's .Iaddend.are alkyl or alkoxy groups, they may be connected together to form a ring, as well as pharmaceutically acceptable salts thereof.These compounds possess a strong antiallergenic action and are thus useful for treatment of asthma, hay fever, .[.anticaria.]. .Iadd.urticaria .Iaddend.and atopic dermatitis.The above aromatic carboxylic amides can be prepared by reacting a reactive functional derivative of the general formula: ##STR2## where R.sub.1, R.sub.2, R.sub.3, R.sub.